Do Lipid Lowering Drugs Reduce the Risk of Coronary Heart Disease?-Reference-Cited by-同舟云学术

Do Lipid Lowering Drugs Reduce the Risk of Coronary Heart Disease?

Published:1998-01 Issue:6 Volume:35 Page:603-621
ISSN:1040-8363
Container-title:Critical Reviews in Clinical Laboratory Sciences
language:en
Short-container-title:Critical Reviews in Clinical Laboratory Sciences

Author:

Pritzker L. B.

Publisher

Informa UK Limited

Subject

Biochemistry, medical,Clinical Biochemistry,General Biochemistry, Genetics and Molecular Biology

Link

http://www.tandfonline.com/doi/pdf/10.1080/10408369891234291

Reference38 articles.

1. McGill HC. Overview. In: Fuster V, Ross R, Topol EJ, eds.Atherosclerosis and coronary artery disease. Pp. 25-41 Philadelphia: Lippincott-Raven Publishers, 1996: vol 1.

2. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management.

3. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

4. Lipid Lowering, Regression, and Coronary Events

5. Review of lipid-lowering clinical trials in relation to observational epidemiologic studies.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dyslipidemia and associated factors among adult cardiac patients: a hospital-based comparative cross-sectional study;European Journal of Medical Research;2024-04-15

2. Synthesis and evaluation of (E)-2-(acrylamido)cyclohex-1-enecarboxylic acid derivatives as HCA1, HCA2, and HCA3 receptor agonists;Bioorganic & Medicinal Chemistry;2014-07

3. Distinct Kinetic and Spatial Patterns of Protein Kinase C (PKC)- and Epidermal Growth Factor Receptor (EGFR)-dependent Activation of Extracellular Signal-regulated Kinases 1 and 2 by Human Nicotinic Acid Receptor GPR109A;Journal of Biological Chemistry;2011-09

4. Discovery of pyrazolyl propionyl cyclohexenamide derivatives as full agonists for the high affinity niacin receptor GPR109A;Bioorganic & Medicinal Chemistry Letters;2010-06

5. Discovery of a Biaryl Cyclohexene Carboxylic Acid (MK-6892): A Potent and Selective High Affinity Niacin Receptor Full Agonist with Reduced Flushing Profiles in Animals as a Preclinical Candidate;Journal of Medicinal Chemistry;2010-02-25